Ipsen receives CHMP recommendation for Cabometyx in combination with Opdivo
March 1, 2021Sales and Marketing Cancer, EMA, ipsen
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Ipsen’s Cabometyx (cabozantinib) in combination with …
MAPs during a global pandemic
February 26, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, MAPS
Early and managed access programmes provide opportunities for patients to get the treatments they need faster – but the COVID-19 …
Pharmafile.com’s top 10 news stories of the week
February 26, 2021Medical Communications news, pharma news, pharmaceuticals, pharmafile, top news stories
COVID-19 news has slowed down in the last week, allowing different pharma developments to take centre stage. In the last …
GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s
February 26, 2021Medical Communications COVID-19, GSK, coronavirus, covid-19 treatment, otilimab
GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has shown promising results in older …
How COVID-19 has changed pharmacovigilance
February 26, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, pharmacovigilance
The race to provide vaccines and treatments for coronavirus has seen a number of COVID-19 drugs reach the market in …
NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer
February 26, 2021Medical Communications Cancer, NICE, Novartis
NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …
MSD acquires Pandion Therapeutics in $1.85bn deal
February 26, 2021Medical Communications MSD, Pandion
MSD, known as Merck in the United States and Canada, has announced that it will acquire clinical-stage biotechnology company Pandion …
Takeda sells four diabetes products to Teijin Pharma for $1.25m
February 26, 2021Medical Communications Takeda
Takeda has entered into an agreement to transfer the assets, marketing rights, and, eventually, marketing authorisation associated with a portfolio …
Ghana is first African country to receive COVID-19 vaccines from COVAX
February 25, 2021The COVAX Facility have delivered their first batch of COVID-19 vaccines to Africa, with 600,000 doses of the Oxford-AstraZeneca vaccine …
Xencor and UCLA TDG partner to develop therapeutic antibodies
February 25, 2021Xencor, ucla
Xencor and UCLA Technology Development Group (UCLA TDG) have announced an agreement to develop novel therapeutic antibodies, pairing novel targets …
Newcells Biotech receive £5m to boost liver and lung condition research
February 25, 2021Stem cell model specialists Newcells Biotech has received £5.25 million in new funding to further their growth in 3D tissue …
NICE issues draft guidance recommending sapropterin for PKU in children
February 25, 2021BioMarin, NICE, PKU
NICE has issued draft guidance which recommends BioMarin’s Kuvan (sapropterin) at a dose of up to 10 mg/kg for treating phenylketonuria …
New research article confirms role of masitinib as a potential pancreatic cancer therapy
February 25, 2021AB Sciences, Cancer, masitinib
A recently published, peer-reviewed research article has concluded that the inhibition of mast cells with AB Science’s masitinib could represent …
UC San Diego School of Medicine researchers treat atopic dermatitis with bacteriotherapy
February 24, 2021Research and Development atopic dermatitis, eczema
Researchers at the University of California San Diego School of Medicine have identified a universal strain of bacteria derived from …
Sanofi and SIRION collaborate on AAV vector development to treat serious diseases
February 24, 2021Research and Development AAV vectors, SIRION, Sanofi
SIRION Biotech and Sanofi have entered into an agreement to develop effective medicines for illnesses impacting major human organs.
QIAGEN and INOVIO to develop diagnostic tests for cervical dysplasia treatment
February 24, 2021Research and Development Inovio, Qiagen, cervical dysplasia
QIAGEN and INOVIO Pharmaceuticals have extended their collaboration to develop a new diagnostic test which identifies the women most likely …
FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin
February 24, 2021Research and Development Bluebird Bio, FDA, sickle cell disease
The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …
RedHill Biopharma to expand COVID-19 opaganib trial to US
February 24, 2021Research and Development COVID-19, RedHill Biopharma
RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of opaganib in patients with severe …
Microsoft and UCB collaborate to treat immunological and neurological diseases
February 23, 2021Manufacturing and Production Microsoft, UCB, artificial intelligence
UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …
Otonomy’s OTIVIDEX ear medicine falls short in Phase III study
February 23, 2021Manufacturing and Production meniere's disease, otividex, otonomy
Otonomy’s OTIVIDEX treatment for Meniere’s disease has failed to meet its primary endpoint in its Phase III trial, the company …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
